Pain in desmoid-type fibromatosis: Prevalence, determinants and prognosis value

Autor: Nicolas Penel, Sylvie Bonvalot, Marie‐Cécile Le Deley, Antoine Italiano, Camille Tlemsani, Diane Pannier, Clémence Leguillette, Jean‐Emmanuel Kurtz, Maud Toulmonde, Julien Thery, Daniel Orbach, Pascale Dubray‐Longeras, Benjamin Verret, François Bertucci, Cécile Guillemet, Lucie Laroche, Armelle Dufresne, Jean‐Yves Blay, Axel Le Cesne
Přispěvatelé: Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, CHU Lille, Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Curie [Paris], Université Paris sciences et lettres (PSL), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut Bergonié [Bordeaux], UNICANCER, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Cité (UPCité), CHU Strasbourg, Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), Institut Gustave Roussy (IGR), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Centre Léon Bérard [Lyon], Ligue Contre le Cancer: PRE2016.LCC/NP, Institut National Du Cancer, INCa, The authors would like to thank the patients and families for their participation in this study, the staff members involved in the trial management and data analysis, in particular Emilie Decoupigny André Michel Bimbaï and Marie Vanseymortier from the sponsorship unit at Centre Oscar Lambret, Lille, all the investigators and their teams who participated in the trial, the patient advocacy group 'SOS Desmoïde,' Françoise Bonichon for her help in literature research and the data managers from Centre de Traitement des Données du Cancéropôle Nord-Ouest (CTD-CNO), who oversaw the trial data management, the CTD-CNO clinical research platform was funded by the French National Cancer Institute (INCa) and 'La Ligue Nationale Contre le Cancer'., This work was supported by a personal grant from a donor (S. Wisnia), the Ligue Nationale Contre le Cancer (PRE2016.LCC/NP), Intersarc (funded by the French National Cancer Institute, INCA), APICIL Foundation and SOS Desmoïde. These funders had no role in the design, conduct or reporting of this work., The authors would like to thank the patients and families for their participation in this study, the staff members involved in the trial management and data analysis, in particular Emilie Decoupigny André Michel Bimbaï and Marie Vanseymortier from the sponsorship unit at Centre Oscar Lambret, Lille, all the investigators and their teams who participated in the trial, the patient advocacy group 'SOS Desmoïde,' Françoise Bonichon for her help in literature research and the data managers from Centre de Traitement des Données du Cancéropôle Nord‐Ouest (CTD‐CNO), who oversaw the trial data management, the CTD‐CNO clinical research platform was funded by the French National Cancer Institute (INCa) and 'La Ligue Nationale Contre le Cancer'.
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: International Journal of Cancer
International Journal of Cancer, 2023, 153 (2), pp.407-416. ⟨10.1002/ijc.34493⟩
ISSN: 0020-7136
1097-0215
DOI: 10.1002/ijc.34493⟩
Popis: International audience; The aim of this study is to evaluate the prevalence, determinants and prognostic value of pain at diagnosis in patients with desmoid-type fibromatosis (DF). We selected patients from the ALTITUDES cohort (NCT02867033), managed by surgery, active surveillance or systemic treatments, with pain assessment at diagnosis. Patients were invited to fill QLQ-C30 questionnaire and Hospital Anxiety Depression Scale. Determinants were identified using logistic models. Prognostic value on event-free survival (EFS) was evaluated using the Cox model. Overall, 382 patients were included in the current study (median age: 40.2 years; 117 men). The prevalence of pain was 36%, without significant difference according to first-line treatment (P =.18). In the multivariate analysis, pain was significantly associated with tumor size >50 mm (P =.013) and tumor site (P
Databáze: OpenAIRE
Externí odkaz: